港股新冠特效藥概念股走強 開拓藥業(9939.HK)三日累漲超50%
格隆匯11月11日丨疫情反覆,港股新冠特效藥概念股開拓藥業近期持續走強,今日盤中一度漲超22%至60.5港元,連續第三日上漲,三日累漲超50%;另一隻新冠特效藥概念股騰盛博藥(2137.HK)目前也漲超15%。國家衞健委今日公佈的數據顯示,11月10日新增確診病例62例,其中本土47例。據悉,開拓藥業的AR拮抗劑普克魯胺,在巴西完成的臨牀試驗顯示療效顯著,並已於7月獲巴拉圭緊急使用授權,目前正在開展住院新冠患者的III期全球多中心臨牀試驗。另外,騰盛博藥的BRII-196/BRII-198聯合療法在三期臨牀試驗中獲得了同類產品的最優數據。今年8月,騰盛博藥公佈的了其隨機雙盲對照的國際三期臨牀試驗數據,該數據顯示在入組的837例疾病進展高風險的新冠門診患者中,此中和抗體聯合療法使住院及死亡率降低78%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.